$PMCB Form 8-K

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.On April 27, 2015, the Board of Directors (“Board”) of PharmaCyte Biotech, Inc., a Nevada corporation (“Company”), appointed Thomas Liquard to the Board to fill a vacancy created by the departure of certain members of the Board in October 2014. Mr. Liquard will be appointed to the Audit Committee of the Board and will serve as its Chairperson.

In connection with Mr. Liquard’s appointment to the Board, the Company entered into a letter agreement with Mr. Liquard pursuant to which the Company agreed to pay Mr. Liquard $9,000 in cash for each calendar quarter of service on the Board and agreed to issue a fully vested option to purchase 250,000 shares of common stock to Mr. Liquard at the fair market value on the date of grant. The Board of Directors approved the issuance of the option on April 27, 2015, and such option has an exercise price of $0.159 per share.

Item 9.01 Financial Statements and Exhibits.(d) Exhibits.

10.1 Letter agreement between the Company and Thomas Liquard dated April 20, 2015.